Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

New drug approvals in oncology


The traditional regulatory drug approval paradigm comprising discrete phases of clinical testing that culminate in a large randomized superiority trial has historically been predominant in oncology. However, this approach has evolved in the current era of drug development, with multiple other development pathways now being utilized. Indeed, treatment approaches designed on the basis of an improved understanding of cancer biology have led to unprecedented responses in early phase trials, sometimes resulting in drug approvals in the absence of large-scale trials. At the same time, improved molecular diagnostic technologies have led to the identification of ever-smaller patient subgroups for molecularly targeted therapy. Moreover, new FDA regulatory paradigms have enabled the rapid review and accelerated approval of certain drugs in the absence of survival data. Regulatory approvals based on large-cohort trials with surrogate or intermediate clinical end points or on non-inferiority trials, as well as new tumour-agnostic indications, also set important precedents in the field. In this Viewpoint, we asked two leading oncologists involved in clinical drug development, an expert in regulatory science and prescription drug policy and a prominent patient advocate, to provide their opinions on the implications of these changes in regulatory practices for patient care.

The contributors

R.K. is the Director of the Center for Personalized Cancer Therapy and founder/director of the Rare Tumor Clinic (as well as Associate Director of the Clinical Science division and Leader of the Experimental Therapeutics Program) at the University of California San Diego Moores Cancer Center. Previously, at MD Anderson Cancer Center, she founded, built up and chaired one of the world’s largest clinical trials departments. Her expertise and interests are in patient-focused precision medicine.

H.M.K. is the Chair of the Leukaemia Department at MD Anderson Cancer Center. He joined the institution in 1981 as a fellow and over the past 38 years has continued his clinical-translational research in leukaemia. He is also a Special Fellow on Healthcare Policies at the Rice Baker Institute and advocates for health-care issues pertinent to patients with cancer and leukaemia.

A.S.K. is a Professor of Medicine at Harvard Medical School and Director of the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. PORTAL is an interdisciplinary research centre focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law.

E.V.S. is the Chairperson and Founder of Friends of Cancer Research, and in addition is the Chair of the Board of Directors at the Reagan–Udall Foundation for the FDA, board member of the Foundation for the National Institute of Health, where she chairs the Portfolio Oversight Committee, and is on the Board of Governors of the Patient-Centered Outcomes Research Institute (PCORI). She also holds leadership positions with a broad range of cancer advocacy, public policy organizations and academic health centres including: MD Anderson Cancer Center External Advisory Board, the Duke University Cancer Center Board of Overseers, and The Sidney Kimmel Comprehensive Cancer Center Advisory Council.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others


  1. Stadtmauer, E. A. et al. Conventional-dose chemotherapy compared with high dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N. Engl. J. Med. 342, 1069–1076 (2000).

    Article  CAS  Google Scholar 

  2. Kurzrock, R., Kantarjian, H. & Stewart, D. J. A cancer trial scandal and its regulatory backlash. Nat. Biotechnol. 32, 27–31 (2014).

    Article  CAS  Google Scholar 

  3. Stewart, D. J., Whitney, S. N. & Kurzrock, R. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J. Clin. Oncol. 28, 2925–2935 (2010).

    Article  Google Scholar 

  4. Tsimberidou, A. M., Braiteh, F., Stewart, D. J. & Kurzrock, R. Ultimate fate of oncology drugs approved by the US Food and Drug Administration without a randomized trial. J. Clin. Oncol. 27, 6243–6250 (2009).

    Article  CAS  Google Scholar 

  5. FDA. CFR - Code of Federal Regulations Title 21 (2019).

  6. Ravandi, F. & Kantarjian, H. Gemtuzumab ozogamicin in acute myeloid leukaemia. Nat. Rev. Clin. Oncol. 9, 310–311 (2012).

    Article  CAS  Google Scholar 

  7. Ravandi, F. et al. Gemtuzumab ozogamicin: time to resurrect? J. Clin. Oncol. 30, 3921–3923 (2012).

    Article  CAS  Google Scholar 

  8. Kantarjian, H. et al. Decitabine in older adults with acute myeloid leukemia: why was the dream broken? J. Clin. Oncol. 31, 1795–1796 (2013).

    Article  Google Scholar 

  9. Kantarjian, H. & Estey, E. Drug approvals in acute myeloid leukemia: can we do better? The ASCO Post (2013).

  10. Kantarjian, H. M. et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 30, 2670–2677 (2012).

    Article  CAS  Google Scholar 

  11. Naqvi, K. et al. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124, 2740–2747 (2018).

    Article  CAS  Google Scholar 

  12. Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740–753 (2016).

    Article  CAS  Google Scholar 

  13. Kantarjian, H. et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 19, 240–248 (2018).

    Article  CAS  Google Scholar 

  14. Jabbour, E. et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 4, 230–234 (2018).

    Article  Google Scholar 

  15. Jabbour, E. et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer 124, 4044–4055 (2018).

    Article  CAS  Google Scholar 

  16. Kantarjian, H. & O'Brien, S. Poor penetration of existing effective chemoimmunotherapy for the treatment of older patients with newly diagnosed acute lymphocytic leukemia (ALL) or refractory/relapsed ALL. J. Oncol. Pract. 15, 77–79 (2019).

    Article  Google Scholar 

  17. Stein, E. et al. Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions. Blood 132, 560 (2018).

    Article  Google Scholar 

  18. DiNardo, C. D. et al. Mutant IDH (MIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). J. Clin. Oncol. 36 (suppl.), 7042–7042 (2018).

    Article  Google Scholar 

  19. Hwang, T. J. et al. Efficacy, safety, and regulatory approval of Food and Drug Administration-designated breakthrough and nonbreakthrough cancer medicines. J. Clin. Oncol. 36, 1805–1812 (2018).

    Article  CAS  Google Scholar 

  20. Olson, M. K. The risk we bear: the effects of review speed and industry user fees on new drug safety. J. Health Econ. 27, 175–200 (2008).

    Article  Google Scholar 

  21. Grabowski, H. & Wang, Y. R. Do faster Food and Drug Administration drug reviews adversely affect patient safety? An analysis of the 1992 Prescription Drug User Fee Act. J. Law Econ. 51, 377–406 (2008).

    Article  Google Scholar 

  22. Mostaghim, S., Gagne, J. J. & Kesselheim, A. S. Safety-related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study. BMJ 358, j3837 (2017).

    Article  Google Scholar 

  23. Kesselheim, A. S., Wang, B., Franklin, J. M. & Darrow, J. J. Trends in utilization of FDA expedited drug development and approval programs, 1987–2014: cohort study. BMJ 351, h4633 (2015).

    Article  Google Scholar 

  24. FDA. 2016 novel drugs summary (2017).

  25. FDA. Advancing health through innovation: 2017 new drug therapy approvals (2018).

  26. FDA. Advancing health through innovation: 2018 new drug therapy approvals (2019).

  27. Chen, E. Y., Joshi, S. K., Tran, A. & Prasad, V. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials. JAMA Intern. Med. 179, 642–647 (2019).

    Article  Google Scholar 

  28. Johnson, K. R. et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 7, 741–746 (2006).

    Article  Google Scholar 

  29. Kurzrock, R. & Stewart, D. J. Equipoise abandoned? Randomization and clinical trials. Ann. Oncol. 24, 2471–2474 (2013).

    Article  CAS  Google Scholar 

  30. Kim, C. & Prasad, V. Strength of validation for surrogate end points used in the US Food and Drug Administration’s approval of oncology drugs. Mayo Clin. Proc. 91, 713–725 (2016).

    Article  Google Scholar 

  31. Kesselheim, A. S., Myers, J. A. & Avorn, J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 305, 2320–2326 (2011).

    Article  CAS  Google Scholar 

  32. [No authors listed]. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Fed. Reg. 57, 13234–13242 (1992).

  33. Micheel, C. M. & Ball, J. R. (eds) Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (National Academies Press, 2010).

  34. Vokinger, K. N. & Kesselheim, A. S. Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs. Health Policy 123, 721–727 (2019).

    Article  Google Scholar 

  35. Powers, J. H., Evans, S. R. & Kesselheim, A. S. Studying new antibiotics for multidrug resistant infections: are today’s patients paying for unproved future benefits? BMJ 360, k587 (2018).

    Article  Google Scholar 

  36. Gyawali, B. & Kesselheim, A. S. FDA approval of new drugs based on non-inferiority trials in oncology: a dangerous precedent? JAMA Oncol. 5, 607–608 (2019).

    Article  Google Scholar 

  37. Naci, H., Smalley, K. R. & Kesselheim, A. S. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA 318, 626–636 (2017).

    Article  Google Scholar 

  38. Gyawali, B., Hey, S. P. & Kesselheim, A. S. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern. Med. 179, 906–913 (2019).

    Article  Google Scholar 

  39. Gellad, W. F. & Kesselheim, A. S. Accelerated approval and expensive drugs — a challenging combination. N. Engl. J. Med. 376, 2001–2004 (2017).

    Article  Google Scholar 

  40. FDA. CFR - Code of Federal Regulations Title 21 (2019).

  41. Stewart, D. J. & Kurzrock, R. Cancer: the road to Amiens. J. Clin. Oncol. 27, 328–333 (2009).

    Article  Google Scholar 

  42. Subbiah, V. & Kurzrock, R. The marriage between genomics and immunotherapy: mismatch meets its match. Oncologist 24, 1–3 (2019).

    Article  Google Scholar 

  43. Shah, P. et al. Artificial intelligence and machine learning in clinical development: a translational perspective. NPJ Digit. Med. 2, 69 (2019).

    Article  Google Scholar 

  44. European Medicines Agency. ICH E6 (R2) Good clinical practice (2016).

  45. FDA. CFR - Code of Federal Regulations Title 21 (2019).

  46. FDA. CFR - Code of Federal Regulations Title 21 (2019).

  47. Good clinical practice network. 4. Investigator (2016).

  48. Kantarjian, H. M. et al. Cancer research in the United States: a critical review of current status and proposal for alternative models. Cancer 124, 2881–2889 (2018).

    Article  Google Scholar 

  49. Kim, E. S. et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. J. Clin. Oncol. 35, 3737–3744 (2017).

    Article  CAS  Google Scholar 

  50. Sherman, R. E. et al. Real-world evidence — what is it and what can it tell us? N. Engl. J. Med. 375, 2293–2297 (2016).

    Article  Google Scholar 

Download references


The work of R.K. is funded in part by the Joan and Irwin Jacobs Fund and by National Cancer Institute grant P30 CA023100. The work of A.S.K. is funded by Arnold Ventures, the Harvard-MIT Center for Regulatory Science, and the Engelberg Foundation.

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Razelle Kurzrock, Hagop M. Kantarjian, Aaron S. Kesselheim or Ellen V. Sigal.

Ethics declarations

Competing interests

R.K. receives research funding from Foundation Medicine, Genentech, Grifols, Guardant Health, Incyte, Konica Minolta, Merck Serono, Pfizer and Sequenom, and consultant fees from Actuate Therapeutics, Genentech, LOXO, NeoMed and X-Biotech. She receives speaker fees from Roche and has an equity interest in Curematch and IDbyDNA. H.M.K. has received research funding from Abbvie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi–Sankyo, Immunogen, Jazz pharma, Novartis and Pfizer, and declares honoraria from Abbvie, Actinium, Agios, Amgen, Pfizer and Takeda. The other contributors declare no competing interests.

Additional information


All comments by Hagop Kantarjian are his personal opinions and do not reflect the opinions of his institutional affiliation.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Related links

FDA Adverse Event Reporting System:

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kurzrock, R., Kantarjian, H.M., Kesselheim, A.S. et al. New drug approvals in oncology. Nat Rev Clin Oncol 17, 140–146 (2020).

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research